About US
Contact us
-
Regeneron to lay off field staffers as it restructures Sanofi partnershipWith its long-standing partnership with Sanofi in its final days, Regeneron is in a belt-tightening phase as it prepares for its new reality. Now, the first blow has landed with some of the New York-2019/12/30
-
Sanofi beat out 3 suitors and one last-minute bid in its pricey $2.5B Synthorx buyoutWhen Sanofi picked up biotech Synthorx for a cool $2.5 billion this month, it paid a rich premium to enter an increasingly competitive immunotherapy field.But in the face of stiff competition, someti2019/12/27
-
AstraZeneca, Merck's Lynparza lands FDA nod in tough-to-treat pancreatic cancerEarlier this month, FDA experts voted—barely—that the agency should approve AstraZeneca and Merck’s Lynparza in pancreatic cancer. But that small majority was enough to convince regulators to follow2019/12/27
-
Allergan scores year-end FDA nod for CGRP migraine med Ubrelvy, plans early 2020 launchThe CGRP migraine prevention field already has three meds from Amgen, Eli Lilly andTeva vying for market share, and now Allergan has scored the first approval for an oral CGRP to treat migraines as t2019/12/26
-
Intra-Cellular nabs nod for schizophrenia drug Caplyta after FDA twists and turnsIntra-Cellular Therapies had quite a journey toward an FDA decision on its antipsychotic contender. It involved mixed clinical data, a canceled advisory committee meeting and a three-month review ext2019/12/26
-
No holiday gift for GSK: FDA sends long-acting HIV injectable back to workHIV patients looking for relief fromthe burden of daily pills will have to wait a little longer. Saturday, GlaxoSmithKline’s ViiV Healthcare said that the FDA hadrejectedits long-acting HIV injection2019/12/25
-
News of Note—UCB's $300M plant; AbbVie's latest Rinvoq nod; Biogen's $5B buyback>UCBis investing more than €300 million ($333 million) to build a new biologics manufacturing facility at its site in Braine l’Alleud, Belgium. Expected to start operating in 2024, the plant will2019/12/25
-
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdlesIn January 2019, then-FDA commissioner Scott Gottlieb ushered in the new year with a bold prediction: The agency, he said, would be approving between 10 and 20 gene and cell therapies per year by 2022019/12/24
-
ArQule wanted a partner. Merck wanted control. Solution? A buyout dealIt’s not uncommon for partnership talks focused on one drug to escalate into a full-on buyout. And that's just what happened with Merck & Co.’s $2.7 billion deal for ArQule. ArQule started lookin2019/12/24
-
Lilly launches real-world study to benchmark Emgality against migraine rivalsEli Lilly’s CGRP migraine prevention medEmgalitytrailed its rivals onto the market, but it’s been a force in the dogfight for market share. Now,in an effort tolearn more about how physicians choose b2019/12/23